Real-world data on cannabidiol treatment of various epilepsy subtypes: A retrospective, multicenter study.
Fabienne KühneLena-Luise BeckerThomas BastAstrid BertscheIngo BorggraefeChristian Malte BoßelmannJörg FahrbachChristoph HertzbergNina A HerzMartin HirschMartin HoltkampChristine JanelloGerhard Josef KlugerGerhard KurlemannHolger LercheKonstantin L MakridisFelix von PodewilsMilka PringsheimSusanne Schubert-BastJuliane SchulzAndreas Schulze-BonhageDavid SteinbartBernhard J SteinhoffAdam StrzelczykSteffen SyrbeHeike De VriesChristiane WagnerJohanna WagnerBernd WilkenChristine PragerKerstin Alexandra KlotzAngela M KaindlPublished in: Epilepsia open (2023)
Our study highlights that CBD has an antiseizure effect comparable to other antiseizure medications with a positive safety profile independent of the epilepsy subtype. Comedication with clobazam was not associated with a better outcome. Higher doses to achieve seizure frequency reduction were safe, particularly in children. These findings call for further trials for an extended approval of CBD for other epilepsy subtypes and for children <2 years of age.